{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:16:16Z","timestamp":1747224976899,"version":"3.40.5"},"reference-count":16,"publisher":"Galenos Yayinevi","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjps"],"published-print":{"date-parts":[[2022,2,25]]},"DOI":"10.4274\/tjps.galenos.2021.63060","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T16:41:54Z","timestamp":1630946514000},"page":"101-103","source":"Crossref","is-referenced-by-count":3,"title":["Multi-drug Treatment for COVID-19-induced Acute Respiratory Distress Syndrome"],"prefix":"10.4274","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6684-6688","authenticated-orcid":false,"given":"Masashi","family":"OHE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1086\/597807","article-title":"The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi","volume":"199","author":"Bernardino","year":"2009","unstructured":"1. Bernardino AL, Kaushal D, Philipp MT. The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi. J Infect Dis. 2009;199:1379-1388.","journal-title":"J Infect Dis"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fimmu.2018.00302","article-title":"The Immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms","volume":"9","author":"Zimmermann","year":"2018","unstructured":"2. Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The Immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms. Front Immunol. 2018;9:302.","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s00011-008-8007-8","article-title":"Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice","volume":"57","author":"Zhang","year":"2008","unstructured":"3. Zhang X, Song Y, Ci X, An N, Ju Y, Li H, Wang X, Han C, Cui J, Deng X. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res. 2008;57:524-529.","journal-title":"Inflamm Res"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Gironi LC, Damiani G, Zavattaro E, Pacifico A, Santus P, Pigatto PDM, Cremona O, Savoia P. Tetracyclines in COVID-19 patients quarantined at home: literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses. Dermatol Ther. 2021;34:e14694.","DOI":"10.1111\/dth.14694"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Tsiakos K, Tsakiris A, Tsibris G, Voutsinas P, Panagopoulos P, Kosmidou M, Petrakis V, Gravvani A, Gkavogianni T, Klouras E, Katrini K, Koufargyris P, Rapti I, Karageorgos A, Vrenzos E, Damoulari C, Zarkada V, Sidiropoulou C, Artemi S, Ioannidis A, Papapostolou A, Michelakis E, Georgiopoulou M, Myrodia DM, Tsiamalos P, Syrigos K, Chrysos G, Nitsotolis T, Milionis H, Poulakou G, Giamarellos-Bourboulis EJ. Oral clarithromycin in COVID-19 of moderate severity: the ACHIEVE open label trial using concurrent matched comparators medRxiv. doi: 10.1101\/2020.12.22.20248753.","DOI":"10.1101\/2020.12.22.20248753"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijid.2020.11.191","article-title":"A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness","volume":"103","author":"Ahmed","year":"2021","unstructured":"6. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, Rahman M, Zaman K, Somani J, Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214-216.","journal-title":"Int J Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. Bangladesh Coll Phys Surg. 2020;38(Supplement Issue):10-15.","DOI":"10.3329\/jbcps.v38i0.47512"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Prasad A. Early administration of ivermectin, azithromycin & doxycycline along with i.v. prednisolone in a case of COVID -19 disease may lead to early recovery? Int J Pharm Chem Anal. 2020;7:149-150.","DOI":"10.18231\/j.ijpca.2020.023"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12985-021-01588-y","article-title":"Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction","volume":"18","author":"Wang","year":"2021","unstructured":"9. Wang J, Yang X, Li Y, Huang JA, Jiang J, Su N. Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction. Virol J. 2021;18:117.","journal-title":"Virol J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1186\/s13054-020-03306-6","article-title":"Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation","volume":"24","author":"Menzella","year":"2020","unstructured":"10. Menzella F, Fontana M, Salvarani C, Massari M, Ruggiero P, Scelfo C, Barbieri C, Castagnetti C, Catellani C, Gibellini G, Falco F, Ghidoni G, Livrieri F, Montanari G, Casalini E, Piro R, Mancuso P, Ghidorsi L, Facciolongo N. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit Care. 2020;24:589.","journal-title":"Crit Care"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jmii.2020.09.007","article-title":"Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19","volume":"54","author":"Chuang","year":"2020","unstructured":"11. Chuang TY, Tsai MH, Wu LM, Ho SJ, Yeh PS, Liu YL, Fred Yang HJ. Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19. J Microbiol Immunol Infect. 2020;54:147-148.","journal-title":"J Microbiol Immunol Infect"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cyto.2009.08.016","article-title":"Ex-vivo effect of dexamethasone on cytokine production from whole blood of septic patients: correlation with disease severity","volume":"49","author":"Giamarellos-Bourboulis","year":"2010","unstructured":"12. Giamarellos-Bourboulis EJ, Dimopoulou I, Kotanidou A, Livaditi O, Pelekanou A, Tsagarakis S, Armaganidis A, Orfanos SE. Ex-vivo effect of dexamethasone on cytokine production from whole blood of septic patients: correlation with disease severity. Cytokine. 2010;49:89-94.","journal-title":"Cytokine"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00134-021-06394-2","article-title":"Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis","volume":"47","author":"Chaudhuri","year":"2021","unstructured":"13. Chaudhuri D, Sasaki K, Karkar A, Sharif S, Lewis K, Mammen MJ, Alexander P, Ye Z, Lozano LEC, Munch MW, Perner A, Du B, Mbuagbaw L, Alhazzani W, Pastores SM, Marshall J, Lamontagne F, Annane D, Meduri GU, Rochwerg B. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med. 2021;47:521-537.","journal-title":"Intensive Care Med"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Byrne JD, Shakur R, Collins JE, Becker S, Young CC, Boyce H, Traverso G. Prophylaxis with tetracyclines in ARDS: Potential therapy for COVID-19-induced ARDS? medRxiv. doi: 10.1101\/2020.07.22.20154542.","DOI":"10.1101\/2020.07.22.20154542"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.21037\/atm.2017.12.25","article-title":"Macrolide therapy is associated with reduced mortality in acute respiratory distress syndrome (ARDS) patients","volume":"6","author":"FD","year":"2018","unstructured":"15. Simonis FD, de Iudicibus G, Cremer OL, Ong DSY, van der Poll T, Bos LD, Schultz MJ; MARS consortium. Macrolide therapy is associated with reduced mortality in acute respiratory distress syndrome (ARDS) patients. Ann Transl Med. 2018;6:24.","journal-title":"Ann Transl Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.5582\/ddt.2021.01005","article-title":"Multidrug treatment for COVID-19","volume":"15","author":"Ohe","year":"2021","unstructured":"16. Ohe M, Furuya K, Goudarzi H. Multidrug treatment for COVID-19. Drug Discov Ther. 2021;15:39-41.","journal-title":"Drug Discov Ther"}],"container-title":["Turkish Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T12:59:32Z","timestamp":1717678772000},"score":1,"resource":{"primary":{"URL":"https:\/\/turkjps.org\/articles\/doi\/tjps.galenos.2021.63060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2,25]]},"published-print":{"date-parts":[[2022,2,25]]}},"URL":"https:\/\/doi.org\/10.4274\/tjps.galenos.2021.63060","relation":{},"ISSN":["1304-530X","2148-6247"],"issn-type":[{"type":"print","value":"1304-530X"},{"type":"electronic","value":"2148-6247"}],"subject":[],"published":{"date-parts":[[2022,2,25]]}}}